Back to search

Article

L3MBTL1, a polycomb protein, promotes Osimertinib Acquired resistance through Epigenetic Regulation of DNA damage response in lung adenocarcinoma

2023-05-18

Abstract excerpt

<title>Abstract</title> <p>Osimertinib is a third generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (EGFR-TKI) that was approved for patients with EGFR T790M resistance mutations as first- or second-line treatment for EGFR-positive patients. Resistance to Osimertinib inevitably develops and the underlying mechanisms are largely unknown. In this study, we discovered that acquired resista...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
0f676fde-9a88-5def-9953-c202794e87c6
DOI
10.21203/rs.3.rs-2799668/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
L3MBTL1, a polycomb protein, promotes Osimertinib Acquired resistance through Epigenetic Regulation of DNA damage response in lung adenocarcinomaDOI 10.21203/rs.3.rs-2799668/v1
L3MBTL1, a polycomb protein, promotes Osimertinib acquired resistance through epigenetic regulation of DNA damage response in lung adenocarcinomaSemantic proximity
The histone-modified landscape: Core mechanisms of osimertinib resistance in EGFR-mutant lung cancer.Semantic proximity
Integrative multi-omics identifies AP-1 transcription factor as a targetable mediator of acquired osimertinib resistance in non-small cell lung cancer.Semantic proximity
A cohort-based multi-omics identifies nuclear translocation of eIF5B /PD-L1/CD44 complex as the target to overcome Osimertinib resistance of ARID1A-deficient lung adenocarcinomaSemantic proximity
Bulk RNA analysis identified the characteristics and immunoinvasive patterns of osimertinib resistance in patients with non-small cell lung cancerSemantic proximity
Mammalian SWI/SNF chromatin remodeling complexes promote tyrosine kinase inhibitor resistance in EGFR-mutant lung cancer.Semantic proximity
Activation of NF-κB/ALDH1A1 Signaling Promotes Non-Mutational Resistance to EGFR-TKIs in Non-Small Cell Lung CancerSemantic proximity
TRMT1-Mediated tRNA m22G Modification Drives Osimertinib Resistance via the ATXN3/USP25 Axis in Lung AdenocarcinomaSemantic proximity
Lnc-TMEM132D-AS1 Confers Acquired Resistance to Osimertinib in Non-Small-Cell Lung CancerSemantic proximity
MDM2 drives resistance to Osimertinib by contextually disrupting FBW7-mediated destruction of MCL-1 protein in EGFR mutant NSCLC.Semantic proximity
Lnc-TMEM132D-AS1 as a potential therapeutic target for acquired resistance to osimertinib in non-small-cell lung cancerSemantic proximity
Intrinsic and Acquired Drug Resistance to LSD1 Inhibitors in SCLC Occurs through a TEAD4 Driven Transcriptional StateSemantic proximity
Select a neighboring publication to make it the new centre.